The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment

作者：Michelle C. Janelsins, Kathleen Van Dyk, Sheri J. Hartman, Thuy T. Koll, Christina K. Cramer, Glenn J. Lesser, Debra L. Barton, Karen M. Mustian, Lynne I. Wagner, Patricia A. Ganz, Peter D. Cole, Alexis Bakos, James C. Root, Kristina K. Hardy, Allison Magnuson, Robert J. Ferguson, Brenna C. McDonald, Andrew J. Saykin, Brian D. Gonzalez, Jeffrey S. Wefel, David A. Morilak, Saurabh Dahiya, Cobi J. Heijnen, Yvette P. Conley, Alicia K. Morgans, Donald Mabbott, Michelle Monje, Stephen R. Rapp, Vinai Gondi, Catherine Bender, Leanne Embry, Worta McCaskill‐Stevens, Judith O. Hopkins, Diane St. Germain, Susan G. Dorsey · 发表于：JNCI Journal of the National Cancer Institute · 年份：2024 · DOI：10.1093/jnci/djae209 · 被引用次数：20 · 研究领域：Cancer-related cognitive impairment studies、Glioma Diagnosis and Treatment、Brain Metastases and Treatment

Cancer-related cognitive impairment is a broad term encompassing subtle cognitive problems to more severe impairment. The severity of this impairment is influenced by host, disease, and treatment factors, and the impairment affects patients before, during, and following cancer treatment. The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee (SxQoL SC) convened a clinical trial planning meeting to review the state of the science on cancer-related cognitive impairment and develop phase II/III intervention trials aimed at improving cognitive function in cancer survivors with non-central nervous system disease and longitudinal studies to understand the trajectory of cognitive impairment and contributing factors. Participants included experts in the field of cancer-related cognitive impairment, members of the SxQoL SC, patient advocates, representatives from all 7 NCI Community Oncology Research Program research bases, and the NCI. Presentations focused on the following topics: measurement, lessons learned from pediatric and geriatric oncology, biomarker and mechanism endpoints, longitudinal study designs, and pharmacological and behavioral intervention trials. Panel discussions provided guidance on priority cognitive assessments, considerations for remote assessments, inclusion of relevant biomarkers, and strategies for ensuring broad inclusion criteria. Three clinical trial planning meeting working groups (longitudinal studi...